ESSA Pharma Inc. is a Canada-based pharmaceutical company that was previously focused on developing therapies for the treatment of patients with prostate cancer. The Company is undergoing a comprehensive review process to review its strategic options to maximize shareholder value.

Employees

Sector

Investment Holding Companies

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 04:00:00 2025-10-08 pm EDT			5-day change	1st Jan Change
0.2012 ^USD	-1.85%		-.--%	-

25-10-09	Alexis Bio, Inc completed the acquisition of ESSA Pharma Inc. for $80.4 million.	CI
25-10-08	ESSA Pharma Inc.(NasdaqGM:EPIX) dropped from NASDAQ Composite Index	CI

Capitalization	9.04M 7.83M 7.18M 6.76M 12.58M 861M 12.78M 85.34M 33.21M 416M 33.93M 33.19M 1.45B	P/E ratio 2023	-5.13x	P/E ratio 2024	-9.4x
Enterprise value	-117M -102M -93.28M -87.76M -163M -11.19B -166M -1.11B -432M -5.41B -441M -431M -18.81B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	100%	Yield 2023 *	-	Yield 2024	-

25-10-09	Alexis Bio, Inc completed the acquisition of ESSA Pharma Inc. for $80.4 million.	CI
25-10-08	ESSA Pharma Inc.(NasdaqGM:EPIX) dropped from NASDAQ Composite Index	CI
25-10-06	Essa securityholders approve acquisition by XenoTherapeutics	RE
25-10-06	Essa securityholders approve acquisition by XenoTherapeutics	RE
25-10-06	ESSA Pharma Shareholders Approve Acquisition by XenoTherapeutics	MT
25-10-03	ESSA Pharma Inc. - Shareholder/Analyst Call
25-09-30	Essa Pharma provides update on its application to the Supreme Court of British Columbia for amended interim order	RE
25-09-24	Essa Pharma amends agreement with XenoTherapeutics	RE
25-09-24	Essa Pharma amends agreement with XenoTherapeutics	RE
25-09-21	ESSA Pharma Inc.(NasdaqCM:EPIX) dropped from S&P Global BMI Index	CI
25-09-10	Essa Pharma to adjourn special meeting to September 29, 2025	RE
25-08-13	ESSA Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
25-08-06	Essa Pharma Inc. Announces Cash Distribution, Payable on August 22, 2025	CI

25-09-30	Essa Pharma provides update on its application to the Supreme Court of British Columbia for amended interim order	RE
24-11-04	Oppenheimer Downgrades ESSA Pharma to Market Perform	MT
24-11-04	Piper Sandler Downgrades ESSA Pharma to Neutral	MT
24-11-04	Jefferies Downgrades ESSA Pharma to Hold, Price Target is $1.70	MT
22-12-14	Oppenheimer Adjusts ESSA Pharma's Price Target to $17 From $23, Maintains Outperform Rating	MT

ESSA Pharma Inc. Stock

Equities

EPIX

CA29668H7085

Investment Holding Companies

Valuation: ESSA Pharma Inc.

Chart: ESSA Pharma Inc.

Latest news : ESSA Pharma Inc.

Last Transcript: ESSA Pharma Inc.

Analysts' recommendations: ESSA Pharma Inc.

Press Releases: ESSA Pharma Inc.

News in other languages: ESSA Pharma Inc.

Quotes and Performance

Course Extremes

Managers and Directors: ESSA Pharma Inc.

Latest insider transactions

Shell Companies

Financials

Company Profile

Income Statement and Estimates

25-10-09	ESSA Announces Completion of Arrangement with XenoTherapeutics	AQ
25-08-25	Essa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash Distribution	AQ
25-08-25	Essa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash Distribution	PR
25-08-14	Essa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash Distribution	PR
25-08-13	ESSA Pharma: Fiscal Q3 Earnings Snapshot	AQ

1 year	0.18	1.94
3 years	0.18	11.67
5 years	0.18	32.81
10 years	0.18	71.8

Manager	Title	Age	Since
Jon Adkins PSD	President	-	2025-10-08
Han-Jie Zhou PRN	Corporate Officer/Principal	-	2018-04-23

Date	Insider	Type	Main position	Quantity	% Market Cap.
25-10-08	Scott Requadt	Issuer sale	Director	30,002	0.0676%
25-10-08	David Wood	Issuer sale	Chief Financial Officer	33,343	0.0751%
25-10-08	Franklin Berger	Issuer sale	Director	784,404	1.7671%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ESSA PHARMA INC.	-1.85%	-.--%	-88.23%	-93.35%	9.52M
AIR GLOBAL PLC	0.00%	-8.24%	-	-	1.26B
PRIME BEING CORP.	-14.57%	-.--%	+123.68%	+658.93%	1.23B
CHURCHILL CAPITAL CORP VII	-0.30%	-.--%	-.--%	-2.73%	915M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	+0.20%	-	-	642M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	-.--%	-.--%	-.--%	600M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.29%	+0.39%	-	-	597M
CANTOR EQUITY PARTNERS IV, INC.	-0.10%	-0.29%	-	-	589M
CHURCHILL CAPITAL CORP XI	+0.68%	+0.68%	-	-	573M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.79%	-0.79%	-	-	557M
Average	-1.65%	-0.84%	+8.86%	+140.71%	697.74M
Weighted average by Cap.	-2.60%	-1.50%	+54.97%	+293.23%

	2023	2024
Net sales	-	-
Net income	-26.58M -23.02M -21.12M -19.87M -37.01M -2.53B -37.59M -251M -97.71M -1.23B -99.81M -97.64M -4.26B	-28.54M -24.72M -22.68M -21.34M -39.74M -2.72B -40.37M -270M -105M -1.32B -107M -105M -4.57B
Net Debt	-148M -128M -118M -111M -206M -14.1B -209M -1.4B -544M -6.82B -556M -544M -23.72B	-126M -109M -100M -94.52M -176M -12.05B -179M -1.19B -465M -5.83B -475M -464M -20.26B